SCOTT KOENIG
Medical Practice in Rockville, MD

6503511, Jan 7, 2003

Apr 6, 1999

09/286981

Theresa M. Wizemann - Potomac MD
Scott Koenig - Rockville MD
Leslie S. Johnson - Germantown MD

MedImmune, Inc. - Gaithersburg MD

A61K 3902

4241901, 4241841, 4242341, 4242371, 4242441, 530300, 530350, 514 2, 514 8

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnositics and/or as protective/treatment agents for pathogenic bacterial species.

6565849, May 20, 2003

Mar 2, 2001

09/797760

Scott Koenig - Rockville MD

MedImmune, Inc. - Gaithersburg MD

A61K 3942

4241471, 4241481, 4241491, 4241551, 4242041, 4242061, 4242081, 4242111, 4242261, 4242271, 4242341, 4242361, 4242771

Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.

2009007, Mar 19, 2009

Aug 5, 2008

12/186065

Scott Koenig - Rockville MD, US
Maria Concetta Veri - Denwood MD, US
Nadine Tuaillon - Gettysburg PA, US
Ezio Bonvini - Rockville MD, US

MACROGENICS, INC. - Rockville MD

A61K 39/395, G01N 33/53, A61P 37/02

4241361, 435 72, 435 721, 435 724

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

2005020, Sep 22, 2005

Jan 10, 2005

11/032644

Elaine Tuomanen - Germantown TN, US
Theresa Wizemann - North Potomac MD, US
H. Masure - Leawood KS, US
Leslie Johnson - Germantown MD, US
Scott Koenig - Rockville MD, US

St. Jude Children's Research Hospital - Memphis TN
Medimmune, Inc. - Gaithersburg MD

C12Q001/68, C07H021/04, A61K039/02, C12N015/74

424190100, 435006000, 435069100, 435252300, 435320100, 530350000, 536023700

This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO: 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N— terminal choline binding protein A truncate. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a N— terminal choline binding protein A truncate. Lastly, this invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use.

7229619, Jun 12, 2007

Nov 28, 2000

09/724531

James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Germantown MD, US

MedImmune, Inc. - Gaithersburg MD

A61K 39/42

4241591, 4241301, 4241341, 4241411, 4241471, 4242111

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

7635568, Dec 22, 2009

Jul 26, 2004

10/900230

James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Boyds MD, US

MedImmune, LLC - Gaithersburg MD

G01N 33/53, A61K 39/12, A61K 39/42

435 71, 4241411, 4241471, 4242111

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

7179900, Feb 20, 2007

Mar 31, 2003

10/403180

James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US
Herren Wu - Boyds MD, US

MedImmune, Inc. - Gaithersburg MD

A61K 39/42, A61K 39/155

536 2353, 4241591, 4242111

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis of a RSV infection.

2009009, Apr 9, 2009

Jul 3, 2008

12/167765

Scott Koenig - Rockville MD, US
Maria Concetta Veri - Denwood MD, US
Nadine Tuaillon - Gettysburg PA, US

MACROGENICS, INC. - Rockville MD

A61K 39/395, C07K 16/28, A61P 35/00

4241361, 53038822, 4241431, 4241331, 5303873

The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

2002001, Feb 14, 2002

May 25, 2001

09/865499

Scott Koenig - Rockville MD, US
Mark Hanson - Clarksville MD, US
JoAnn Suzich - Washington Grove MD, US
Nancy Ulbrandt - Gaithersburg MD, US

A61K039/12, A61K039/42

424/186100, 424/147100

The present invention relates to a vaccine that comprises selected epitopes within the F protein structure that have been proven to specifically interact with known potent neutralizing antibodies while simultaneously being presented as part of a synthetic structure that offers these epitopes apart from the other non-neutralizing antigenic determinants of the virus but held in a native conformational form and thereby capable of eliciting neutralizing antibodies.

2009001, Jan 15, 2009

Jul 3, 2008

12/167784

Scott Koenig - Rockville MD, US
Maria Concetta Veri - Denwood MD, US

MACROGENICS, INC. - Rockville MD

A61K 39/395, C07K 16/28, C07K 16/46

4241331, 5303891, 5303873, 5303917, 4241721

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.